Vipul Jairath

Active 2010–2025

310
Papers
18,164
Citations
72
h-index
270
i10-index

Citations

Citations per year for Vipul Jairath1982: 1 citations2004: 1 citations2011: 1 citations2012: 1 citations2013: 5 citations2014: 9 citations2015: 13 citations2016: 23 citations2017: 40 citations2018: 79 citations2019: 333 citations2020: 557 citations2021: 655 citations2022: 814 citations2023: 813 citations2024: 1,569 citations2025: 1,009 citations2026: 33 citations1983–2003: no citations, so these years are not shown2005–2010: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,415 citing papers, 16.8% of this breakdownUnited Kingdom: 684 citing papers, 8.1% of this breakdownChina: 682 citing papers, 8.1% of this breakdownCanada: 621 citing papers, 7.4% of this breakdownItaly: 605 citing papers, 7.2% of this breakdownFrance: 397 citing papers, 4.7% of this breakdownGermany: 349 citing papers, 4.2% of this breakdownNetherlands: 342 citing papers, 4.1% of this breakdownSpain: 293 citing papers, 3.5% of this breakdownBelgium: 247 citing papers, 2.9% of this breakdownAustralia: 234 citing papers, 2.8% of this breakdownJapan: 222 citing papers, 2.6% of this breakdown
0%16.8%Other 27.6%

Fields

  • Biochemistry, Genetics and Molecular Biology51.8%
  • Medicine37.8%
  • Immunology and Microbiology4.6%
  • Neuroscience0.9%
  • Agricultural and Biological Sciences0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Other3.7%

Topics

  • Inflammatory Bowel Disease18.3%
  • Microscopic Colitis6.5%
  • Gut microbiota and health3.3%
  • Gastrointestinal Bleeding Diagnosis and Treatment3%
  • Autoimmune and Inflammatory Disorders2.8%
  • Rheumatoid Arthritis Research and Therapies2.3%
  • Other63.8%

Coauthors

All papers

Open in search
  1. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Gastroenterology & Hepatology 2023 cited by 231

  2. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clint Behrend, Geert Bezemer, Guillaume Bonnaud, Marija Branković, Ik Jang Byung, Xavier Calvet, Karen A. Chachu, Júlio Maria Fonseca Chebli, Jae Hee Cheon, Halina Cichoż‐Lach, Larry Clark, Fraser Cummings, Kunal Dalal, Silvio Danese, Nanne K.H. de Boer, Maria de Lourdes Abreu Ferrari, Étienne Désilets, Predrag Dugalić, George Duvall, Olga Fedorishina, Rafał Filip, Cristina Flores, Ronald Fogel, James Fon, Michael Frankel, Keith Friedenberg, Walter Fries, Vassileva Galina, Piotr Gietka, Rishi Goel, Peter Hasselblatt, Hans Herfarth, László Herszényi, Pieter Hindryckx, Frank Hoentjen, Carmen Horjus Talabur Horje, Satish Iduru, Peter M. Irving, Robert J. Isfort, Vipul Jairath, Michael Jones, Dilara Kalimullina, Jeffry Katz, Manreet Kaur, Sunil K Khurana, Joo Sung Kim, Young‐Ho Kim, D Kleczkowski, Slavko Knezevic, Aaron Knoll, Louis Y Korman, Iskren Kotzev, Andrey Kulyapin, Kang‐Moon Lee, Desirée Leemreis, Jarosław Leszczyszyn, Jimmy K. Limdi, Jack J. Lissauer, Edward V. Loftus, Ewa Małecka‐Panas, John K. Marshall, Emese Mihály, Lukáš Milan, Giovanni Monteleone, Aleksandar Nagorni, Danuta Owczarek, Nichole Palekar, Remo Panaccione, Young Soo Park, Sang Hyoung Park and 43 more - The Lancet 2022 cited by 297

  3. Global burden of inflammatory bowel disease

    Authors: , - ˜The œLancet. Gastroenterology & hepatology 2019 cited by 363

  4. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis

    Authors: , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2021 cited by 294

  5. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alan A. Wiles, Horace R. Williams, Gijs R. van den Brink, Séverine Vermeire, Vipul Jairath, Geert D’Haens, Eoin McKinney, Paul Lyons, James O. Lindsay, Nicholas A. Kennedy, Kenneth G. C. Smith, Miles Parkes, Nurulamin M Noor, James Lee, Simon Bond, Francis Dowling, Biljana Brezina, Kamal Patel, Tariq Ahmad, Paul Banim, James Berrill, Rachel Cooney, Juan De La Revilla Negro, Shanika de Silva, Shahida Din, Dharmaraj Durai, J Gordon, Peter M. Irving, Matthew W. Johnson, Alexandra Kent, Klaartje Kok, Gordon W. Moran, Craig Mowat, Pritash Patel, C Probert, Tim Raine, Rebecca Saich, Abigail Seward, Dan Sharpstone, Melissa Smith, Sreedhar Subramanian, Sara Upponi, Alan A. Wiles, Horace R. Williams, Gijs van Den Brink, Séverine Vermeire, Vipul Jairath, Geert D’Haens, Eoin McKinney, Paul Lyons, James O. Lindsay, Nicholas A. Kennedy, Kenneth G. C. Smith, Miles Parkes, Clare Allcock, Suhaylah Bhatti, Jonathan Blackwell, Robert Boulton-Jones, Matthew Brookes, Rhys O. Butcher, Jeffrey Butterworth, Karlena Champion, Rakesh Chaudhary, Andy Cole, Lauranne Derikx, Anjan Dhar, Mary Flowerdew, Rishi Goel, Ailsa Hart, R Hughes and 17 more - ˜The œLancet. Gastroenterology & hepatology 2024 cited by 281

  6. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population-Based Cohorts

    Authors: , , , , , , , , , - Clinical Gastroenterology and Hepatology 2020 cited by 308

  7. Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review

    Authors: , , , , , , , , , , , , - Gut 2019 cited by 303

  8. An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease

    Authors: , , , , , , , , , , , , , , , , , , , , - Alimentary Pharmacology & Therapeutics 2018 cited by 258

  9. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease

    Authors: , , , , , , , , , , , , , , - Gastroenterology 2021 cited by 149

  10. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis

    Authors: , , , , , , , , - Gastroenterology 2020 cited by 210

  11. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease

    Authors: , , , , , , , , , , , , , , , , , - Nature Reviews Gastroenterology & Hepatology 2022 cited by 131

  12. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting

    Authors: , , , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2023 cited by 120

  13. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2019 cited by 626

  14. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER)

    Authors: , , , , , , , , , , , , - Clinical Gastroenterology and Hepatology 2023 cited by 88

  15. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

    Authors: , , , , , , , , , , , , , - Gastroenterology 2021 cited by 120

  16. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon Travis, Flávio Steinwurz, Dan Turner, Parambir S. Dulai, Vipul Jairath, Iris Dotan, María T. Abreu, Remo Panaccione, Silvio Danese - Gastroenterology 2021 cited by 165

  17. Navigating the complexities of drug development for inflammatory bowel disease

    Authors: , , , - Nature Reviews Drug Discovery 2024 cited by 96

  18. Development and validation of a histological index for UC

    Authors: , , , , , , , , , , , , , , , , , , , , - Gut 2015 cited by 349

  19. Vedolizumab for the Treatment of Chronic Pouchitis

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 112

  20. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alan Barkun, Suresh S. David, P.J. Devereaux, Tony Brady, Ian Roberts, Haleema Shakur‐Still, Tim Coats, Phil Edwards, Ian Gilmore, Vipul Jairath, Katharine Ker, Daniela Manno, Simon Stanworth, Andrew Veitch, Mònica Arribas, Emma Austin, Kiran Bal, Eni Balogun, Collette Barrow, Danielle Beaumont, Myriam Benyahia, Amy Brenner, Imogen Brooks, Madeleine Cargill, Laura Carrington, Phil Edwards, Lauren Frimley, Amber Geer, Daniel Gilbert, Catherine Gilliam, Julio Gil Onandia, Nayia Golfi, Daniel Hetherington, Courtenay Howe, Carolyn Hughes, David I'Anson, Rob Jackson, Miland Joshi, Sneha Kansagra, Taemi Kawahara, Katharine Ker, Sergey Kostrov, Daniela Manno, Raoul Mansukhani, Hakim Miah, B. Ndungu, Kelly Needham, Aroudra Outtandy, Daniel Pearson, Tracey Pepple, Danielle Prowse, Nigel Quashi, Anna Quinn, Maria Ramos, Laura Ranopa, Mia Reid, Ian Roberts, Chris Roukas, Haleema Shakur‐Still, Chelci Squires, Jemma Tanner, Andrew Thayne, Ruhama Uddin, Rizwana Chaudhri, Muttiullah Mutti, Kiran Javaid, Aasia Kayani, Bukola Fawole, Folasade Adenike Bello, Oladapo Olayemi and 414 more - The Lancet 2020 cited by 389

  21. Epidemiology and Natural History of Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts

    Authors: , , , , - Inflammatory Bowel Diseases 2021 cited by 137

  22. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)

    Authors: , , , - Gut 2022 cited by 74

  23. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies

    Authors: , , , - Trials 2014 cited by 518

  24. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Bossuyt, Marc Ferrante, Fabio Luiz Maximiano, Lígia Yukie Sassaki, Carolina Baía, D. Poli, A D S Carlos, Carlos Fernando de Magalhães Francesconi, Alexander De Sa Rolim, J. Razera, Joaquim Simões Neto, Rodrigo Rocco, Jonathas Stifft, Jonathan Soldera, Jonathas Stifft, C. Clemente, Sandra Di Felice Boratto, Luciana Teixeira de Campos, Marcelo Rodrigues Borba, Gregory Rosenfeld, Terry Ponich, Allen Lim, Chadwick Williams, Bruce Musgrave, Chadwick Williams, Wenjia Liu, Chengdang Wang, Hong Guo, Chunxiao Chen, Yan Chen, Qian Cao, Jie Zhong, Min Xu, Yufang Wang, Changqing Zheng, Xiang Gao, Youxiang Chen, Yinglei Miao, Lin Wang, Deliang Liu, Bangmao Wang, Zhengji Song, Xiaowei Liu, Baili Chen, Wen Jiang, Qiang Zhan, Kaiguang Zhang, Hong Shen, Zhaotao Li, Xiaoyan Wang, Zhaotao Li, Dean Tian, Leilei Chen, Wen Tang, Vladimir Borzan, Željko Krznarić, Miroslava Volfová, Jiri Pumprla, Lucie Veberova, Michal Tichý, Jan Gregar, David Stepek, Jan Ulbrych, Pavel Drastich, Zdenek Papik, Jan Matouš, Martin Lukáš, Radka Koskova, Jan Fallingborg, Romain Altwegg and 245 more - The Lancet 2024 cited by 102